Promising Proof-of-Concept study results to be reported for PNB01 in Major Depression

09-Feb-2010 - Belgium

PharmaNeuroBoost (PNB) reported that the results of it’s phase II Proof-of-Concept study with PNB01 in Major Depression will be presented at the 18th European Congress of psychiatry on March 2nd in Munich.

“The results are impressive and promising”, says Chief Investigator Alan Wade (Glasgow), who has a longstanding expertise in antidepressant clinical research, and who will be presenting the data personally. “Antidepressant treatment still can benefit from substantial improvement in efficacy and speed of onset”, Wade continues, “and the results obtained with PNB01 in this double-blind randomized study may represent a breakthrough in this respect, if further confirmed”.

PNB01 is the first of two front-running proprietary projects of Pharmaneuroboost. “We are very happy with the positive results of the Proof-of-Concept study, and are looking forward to starting phase III development soon”, says Chief Science Officer and Chief Executive Officer Erik Buntinx, psychiatrist, who was first to identify and report the beneficial clinical effects of PNB01 in patients.

PNB01 is the combination of citalopram and a low dose of pipamperone. Citalopram is a well-established antidepressant of the Selective Serotonin Reuptake Inhibitors (SSRI) class. Pipamperone is a well established mild neuroleptic agent that has been used extensively in some European countries for many years.

https://www.bionity.com/en/news/112941/promising-proof-of-concept-study-results-to-be-reported-for-pnb01-in-major-depression.html